# N-Acetyl Selank: What the Research Shows

> N-Acetyl Selank is an acetylated variant of the Selank peptide. What it is, how it relates to the studied Selank research base, and the honest limits of the evidence. Cited throughout.

An acetylated form of the same heptapeptide — what it is, how it maps onto the published Selank literature, and where the evidence runs out.

## The short version

**N-Acetyl Selank** is a slightly modified version of the Selank peptide. The "N-acetyl" part means a small chemical cap (an acetyl group) is added to one end of the molecule, a common trick used to make peptides more stable. The base molecule is still Selank: the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, a stabilized analogue of the natural immune peptide tuftsin, studied as a calm-without-sedation anxiolytic and nootropic. Here is the honest framing, up front: the deep, citable research body — GABA modulation, enkephalinase inhibition, BDNF, immune effects — was built on Selank itself, and this site documents that base literature. N-Acetyl Selank is best understood as a stability-focused variant of that studied peptide, not as a separately proven compound. It is not FDA-approved and is sold only as a research chemical.

## What the acetyl modification means

Adding an N-terminal acetyl group is a standard peptide-chemistry approach intended to slow enzymatic breakdown and improve stability. It is conceptually similar in goal to what already makes Selank what it is: the parent peptide is native tuftsin extended with a C-terminal Pro-Gly-Pro tail specifically to dramatically slow the enzymatic degradation that limits tuftsin [6]. So the design logic behind N-Acetyl Selank — protect the molecule from peptidases so more of it survives — is the same logic that produced Selank in the first place. The underlying sequence and intended biology are Selank's; the acetyl cap is a stability modification layered on top.

## How it relates to the studied Selank research

The substantive, citable findings on this site are findings about Selank. Selank acts as a positive allosteric modulator of GABA receptor binding [1], inhibits enkephalin-degrading enzymes in human plasma with an IC50 around 15 µM [2], raises hippocampal BDNF after intranasal administration in rats [3], shifts 45 then 22 GABA-pathway genes at a 300 µg/kg dose [4], and shows immunomodulatory Th1/Th2 effects in patients [5]. Because N-Acetyl Selank shares the Selank sequence, these mechanisms are the relevant research context for understanding it. What the published record does not provide is a large, independent body of head-to-head data proving the acetylated form behaves identically — so the right move is to read N-Acetyl Selank against the Selank evidence base while not overstating that the variant has been separately validated to the same depth.

## The honest limits

The caveats that apply to Selank apply here, and one more is layered on. Selank's evidence is overwhelmingly from a small set of Russian research groups, often in Russian-language journals with English abstracts only, with limited independent Western replication; human pharmacokinetics are poorly characterized; and Selank is not approved by the FDA or EMA [16][6]. On top of that, the additional N-acetyl modification means the most rigorous studies — the GABA, enkephalinase, BDNF, and clinical anxiety work — were generally done on Selank, not on the acetylated variant specifically. N-Acetyl Selank is sold strictly as a research chemical and is not intended for human use. The reported effects and cautions documented across this site come from the Selank literature; see [Selank effects](/effects) for what people report and the cited safety context.

---

A hopeful read of the Selank research, told honestly — editorial summaries of the published science, never medical advice.